FEDERAL COURT OF AUSTRALIA
Eli Lilly and Company Limited v Apotex Pty Ltd [2013] FCA 214
Citation: Eli Lilly and Company Limited v Apotex Pty Ltd [2013] FCA 214 Parties: ELI LILLY AND COMPANY LIMITED and ELI LILLY AUSTRALIA PTY LTD (ABN 39 000 233 992) v APOTEX PTY LTD (ABN 52 096 916 148) File number: VID 876 of 2009 Judge: MIDDLETON J Date of judgment: 15 March 2013 Catchwords: INTELLECTUAL PROPERTY – Patents – Construction of claims – Infringement of claims – Applicable principles – Skilled addressee – Revocation for invalidity – Novelty – Generic chemical disclosure – Prior art and common general knowledge – Selection patents – Inventive step – Secondary considerations – Commercial success – Sufficiency – Fair basis – Lack of clarity – Manner of new manufacture Legislation: Patents Act 1903-1950 (Cth)
Patents Act 1949 (UK)
Patents Act 1952 (Cth)Patents Act 1952-1955 (Cth)
Patents Act 1990 (Cth)Cases cited: Advanced Building Systems Pty Limited v Ramset Fasteners (Aust) Pty Limited (1998) 194 CLR 171
Aktiebolaget Hässle v Alphapharm Pty Limited (2002) 212 CLR 411
Aktiebolaget Hässle v Alphapharm Pty Ltd (1999) 44 IPR 593; [1999] FCA 628
Alphapharm Pty Ltd v H Lundbeck A/S (2008) 76 IPR 618; [2008] FCA 559
American Home Products Corporation [1994] APO 58 (28 September 1994)
Apotex Pty Ltd (formerly GenRx Pty Ltd) v Sanofi-Aventis (2008) 78 IPR 485; [2008] FCA 1194
Apotex Pty Ltd v AstraZeneca AB (No 4) [2013] FCA 162
Apotex Pty Ltd v Sanofi-Aventis (2009) 82 IPR 416; [2009] FCAFC 134
Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 2) (2012) 204 FCR 494
Australian Mud Company Pty Ltd v Coretell Pty Ltd (2011) 93 IPR 188; [2011] FCAFC 121
Beecham Group Ltd v Bristol Laboratories International SA (1978) RPC 521
Bristol-Myers Co v L’Oreal (1988) 12 IPR 275
Bristol-Myers Co v L’Oreal (1988) 12 IPR 275
Bristol-Myers Co v L’Oreal (1989) 16 IPR 652
Bristol-Myers Squibb Co v F H Faulding & Co Limited (2000) 97 FCR 524
Britax Childcare Pty Ltd v Infa-Secure Pty Ltd (2012) 290 ALR 47
British Acoustic Films Ltd v Nettlefold Productions (1936) 53 RPC 221
British Thomson-Houston Co Ltd v Corona Lamp Works Ltd (1922) 39 RPC 49
Ccom Pty Ltd v Jiejing Pty Ltd (1994) 51 FCR 260
Clay v ICI Australia Operations Pty Ltd (1984) 3 IPR 439
Commissioner of Patents v Ethyl Corporation (1969) 120 CLR 594
Commissioner of Patents v Microcell Limited (1959) 102 CLR 232
Commissioner of Patents v The Wellcome Foundation Limited (1983) 2 IPR 156
Commonwealth Industrial Gases Ltd v MWA Holdings Pty Ltd (1970) 180 CLR 160
Conor Medsystems Inc v Angiotech Pharmaceuticals Inc [2008] 4 All ER 621
Conor Medsystems Inc v University of British Columbia (2005) 223 ALR 74
Décor Corporation Pty Ltd v Dart Industries Inc (1988) 13 IPR 385
Dr Reddy’s Laboratories (UK) Ltd v Eli Lilly and Co Ltd [2010] RPC 9
Dura-Post (Aust) Pty Ltd v Delnorth Pty…
Keep reading for free
Create a free CaseChat account to read Eli Lilly and Company Limited v Apotex Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2013] FCA 214
- Decision Date
CaseChat Overview and Summary
The court first examined the patent's novelty, considering whether olanzapine was disclosed in the prior art, specifically the genus patents. Eli Lilly argued that olanzapine was not disclosed in the prior art, while Apotex contended that it was. The court found that olanzapine was not disclosed in the prior art and thus the patent was novel. Regarding inventive step, the court assessed whether olanzapine, as claimed, involved an inventive step over the prior art. The court held that olanzapine did indeed involve an inventive step because it possessed advantages over prior art compounds, such as fewer side effects and greater efficacy. On the issue of sufficiency of description, the court determined whether the patent sufficiently described the invention to enable a person skilled in the art to replicate it. The court concluded that the patent provided a full and enabling description of olanzapine and its advantages.
In summary, the court found that the patent was valid and that Apotex had infringed it. The court granted Eli Lilly the declarations and injunctions it sought, affirming the patent's validity and prohibiting Apotex from manufacturing, using, or selling olanzapine without Eli Lilly's consent.
Background
Background to the litigation
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
From these data, the Patent concludes at p 14: This profile of activity in in vitro receptor binding assays, like that observed in the behavioural tests, would indicate that the compound is effective in the treatment of psychotic conditions but is less likely to induce extra pyramidal side-effects. Dosage and Administration The Patent teaches the dosage range that is effective to treat different conditions, including mild anxiety and psychotic disorders in adult humans. The Patent also discusses methods of administration of pharmaceutical compositions containing olanzapine, including suitable carriers for olanzapine and formulations thereof (at pp 14-16). Examples The invention is then illustrated by examples. Pages 17 to 23 of the Patent give details of seven examples. The first two examples describe two different ways to synthesise olanzapine. The remaining five examples relate to pharmaceutical formulations containing olanzapine. The Invention Claimed The specification ends in seven claims.(a)Claim 1 is directed to a single compound (namely, 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine) or its acid addition salts.(b)Claim 2 is limited to the single compound (2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine) which is the subject of claim 1.(c)Claims 3 and 4 are directed to pharmaceutical compositions which include the compound of claim 1 or its acid addition salts with a diluent or carrier.(d)Claim 5 is directed to a process for producing the compound of claim 1.(e)Claim 6 is directed to an intermediate compound associated with the production of the compound of claim 1.(f)Claim 7 is an “omnibus” claim. I note that only claims 1 to 4 and 7 are in issue in this proceeding.WITNESSES Eli Lilly relied on the following witnesses: (a)Dr Alan Duncan Robertson, who swore affidavits dated 16 December 2010, 24 June and 12 September 2011. Dr Robertson was cross-examined. Dr Robertson holds a Bachelor of Science (Hons) Degree (1978) and a PhD in synthetic organic chemistry (1981) from the University of Glasgow. Dr Robertson completed a post-doctoral fellowship with the Science and Engineering Research Council at the University of Sussex between 1981 and 1984. He then worked for Wellcome Foundation Ltd where, as a Senior Research Scientist, he worked on a migraine drug marketed as Zomig. In 1992 Dr Robertson migrated to Australia to work for FH Faulding and Company Limited where he managed the development of generic injectable drugs. This role involved reading patents and working the inventions described. (b)Professor David Earl Nichols, who swore affidavits dated 17 December 2010 and 24 June 2011. Professor Nichols was cross-examined. Professor Nichols received a Bachelor’s Degree in Chemistry in 1969 from the University of Cincinnati, and a PhD in Medicinal Chemistry from the University of Iowa in 1973. He completed two years of post-doctoral work there and then moved to Purdue University, where he is currently the Robert C and Charlotte P Anderson Distinguished Chair in Pharmacology. At the priority date, Professor Nichols was a Professor of Pharmacology and Medicinal Chemistry at Purdue University. He has conducted research into drugs that modify consciousness and dopamine receptors, and has particular expertise in the study of small molecules affecting the CNS.(c)Dr Benventuto Capuano, who affirmed an affidavit dated 1 July 2011. Dr Capuano was cross-examined. At the time of swearing his affidavit, Dr Capuano was a Senior Lecturer at the Faculty of Pharmacy & Pharmaceutical Sciences, Monash University. He completed a Bachelor of Applied Science (Applied Chemistry) Degree in 1987, followed by a Master of Pharmacy (1991) and a PhD with the Department of Medicinal Chemistry at Monash University (2001). At the priority date, Dr Capuano was a Masters student and Assistant Lecturer at the Victorian College of Pharmacy. Dr Capuano’s PhD was entitled “The Design, Synthesis and Pharmacological Evaluation of Clozapine Analogues for the Treatment of Schizophrenia”. This examined the differences between “typical” and “atypical” antipsychotic drugs, the available antipsychotic drugs before the priority date and their structural features. Dr Capuano’s PhD included a discussion on key textbooks in the area. (d)Dr Ian Alexander Pullar, who affirmed an affidavit dated 28 July 2011, which largely related to a witness statement that he gave in proceedings regarding the United Kingdom equivalent of the Patent. Dr Pullar was cross-examined. Dr Pullar, a neuropsychopharmacologist, received a Bachelor of Science Degree in 1966 and completed a PhD in Neuroscience in 1971. He was an employee of Eli Lilly from June 1975 until his retirement on 31 January 2005. From 1975 to 1987, Dr Pullar was Head of the CNS Pharmacology group at an Eli Lilly research facility, Erl Wood, in Surrey, United Kingdom. After 1987, he continued as a Senior Research Scientist within Eli Lilly’s Global CNS Pharmacology group. The Pharmacology group was responsible for the research of drugs for the treatment of schizophrenia and depression. (e)Professor Gordon Frederick Stuart Johnson, who swore an affidavit dated 17 May 2011. Professor Johnson was cross-examined. At the time of swearing his affidavit, Professor Johnson was an Emeritus Professor of Psychological Medicine at the University of Sydney. Professor Johnson completed a Bachelor of Medicine Degree and Bachelor of Surgery Degree in 1959. From 1963 to 1964, Professor Johnson trained in psychological medicine in Sussex, UK, and received a Diploma of Psychological Medicine from the Royal College of Physicians & Surgeons UK. Between 1969 and 1970, Professor Johnson was a co-investigator in clinical trials relating to drugs used to treat schizophrenia and bipolar disorder. From 1970 to 1971, he was actively involved in clinical research with new potential psychotropic compounds (drugs for treating mental illnesses) at Schering and Ciba Pharmaceuticals. Professor Johnson has published over 100 articles, reviews, and chapters in books.(f)Professor Guy Manning Goodwin, who swore affidavits dated 4 July 2011 and 18 October 2011. Professor Goodwin was not cross-examined. At the time of swearing his first affidavit, Professor Goodwin was the Head of the Department of Psychiatry and WA Handley Professor of Psychiatry at Merton College, University of Oxford. He was, and has been since 1980, a practising psychiatrist. Professor Goodwin has authored or co-authored over 300 scientific papers, review articles and technical publications in the areas of neuroscience, psychiatry and disorders and function of the CNS. Of these, 35 were co-authored with Australian colleagues. (g)Dr Jeffery Allen Engelhardt, who swore an affidavit dated 24 June 2011. Dr Engelhardt was cross-examined. At the time of swearing his affidavit, Dr Engelhardt was a President and Senior Pathologist of Experimental Pathology Laboratories Incorporated. Dr Engelhardt was employed by Eli Lilly and Company Ltd from 1988 to February 2004 as a veterinary pathologist. His affidavit largely concerned his involvement in animal toxicity studies, conducted in relation to the development of olanzapine, in particular, the dog study D07290 (Lilly Dog Study) conducted by Eli Lilly. (h)Professor John Emery Bauer, who affirmed an affidavit dated 29 June 2011. Professor Bauer was not cross-examined. His affidavit largely concerned the Lilly Dog Study and comparative dog toxicology studies. Professor Bauer was not involved in the Lilly Dog Study. Professor Bauer was, at the time of affirming his affidavit, a Professor at Texas A&M University and a Director of the Comparative Nutrition Research Laboratory at the College of Veterinary Medicine at the same institution. Professor Bauer conducted research on animal nutrition and metabolism, particularly focusing on cholesterol, lipoprotein and serum lipid metabolism in companion animals such as dogs.(i)Professor Ronald Thisted, who swore an affidavit dated 28 June 2011. Professor Thisted was not cross-examined. Professor Thisted was, at the time of swearing his affidavit, the Chairman of the Department of Health Studies at the University of Chicago, as well as a Professor of the Departments of Statistics, Health Studies, Anesthesia and Critical Care and the Undergraduate College at the University of Chicago. He was also a Professor of the Committee on Clinical Pharmacology and Pharmacogenomics. Professor Thisted obtained a PhD in statistics from Stanford University in 1977, and has published a book on statistical computation and over 100 original articles in peer-reviewed journals (including medical journals). He has also published peer-reviewed articles in statistics journals. Professor Thisted’s evidence largely concerned the interpretation and analysis of the Lilly Dog Study and comparative dog toxicology studies. (j)Dr Karl Arthur Traul, who affirmed an affidavit dated 24 June 2011. Dr Traul was not cross-examined. At the time of affirming his affidavit, Dr Traul was the President of K A Traul Pharmaceutical Consulting. Dr Traul obtained a Bachelor’s Degree in Biology in 1963 from the University of Akron, Ohio, a Master of Science in 1965 and later a PhD from Ohio State University in 1969. Between 1969 and 1980 he worked in cancer research and drug safety for Pfizer Pharmaceuticals, ultimately as Laboratory Head and Project Leader. Dr Traul then worked in the area of toxicology for various companies, including Exxon Corporation and American Cyanamid. From 1995 he has worked as a consultant in toxicology and regulatory affairs. Dr Traul largely gave evidence on the Lilly Dog Study and comparative dog toxicology studies.(k)Mr Steven Michael Harrill, who affirmed an affidavit dated 19 August 2011. Dr Harrill was cross-examined. Dr Harrill was, at the time of affirming his affidavit, the Global Brand Director – Neuroscience, of Eli Lilly and Company (US). Mr Harrill has a Bachelor’s Degree in Chemistry and Masters of Business Administration. Mr Harrill has worked for Eli Lilly and Company (US) since July 1985 in various positions. Mr Harrill largely gave evidence on the marketing and sales of various Eli Lilly products.(l)Ms Shihui Yuan, who affirmed an affidavit dated 3 August 2011. Ms Yuan was not cross-examined. Ms Yuan is the Marketing Director of the Bio-medicines business unit of the second applicant, Eli Lilly Australia, and has been so since May 2011. Ms Yuan has an American Language and Literature Degree. After graduating, Ms Yuan worked for Shanghai Loudon Far East, which was a market research firm specialising in the pharmaceutical industry. Since 2001 Ms Yuan has held various marketing roles at Eli Lilly. In her various roles, she has had considerable responsibility for the marketing of Zyprexa products, which contain olanzapine as their active ingredients. Ms Yuan largely gave evidence on the sales of Zyprexa products, and the market share enjoyed by Eli Lilly for these products.(m)Dr Andreas von Falck, who swore an affidavit dated 1 August 2011. Dr von Falck was not cross-examined. Dr von Falck is a partner at the law firm Hogan Lovells International LLP, in the Düsseldorf office. Dr von Falck holds a PhD in International Civil Procedural Law from Freiburg University. Since the European Autumn of 2006, Dr von Falck has represented Eli Lilly in the German proceedings relating to European Patent EP 0454436, the corresponding patent to the Australian Patent in suit. Dr von Falck gave evidence as to steps he undertook to locate a Professor Mager. Professor Mager was co-author of an article known as the “Schauzu Article” (or simply “Schauzu”) in this proceeding.(n)Ms Miriam Gundt, who affirmed an affidavit dated 1 August 2011. Ms Gundt was not cross-examined. Ms Gundt was a colleague (Senior Associate) of Dr von Falck at Hogan Lovells International LLP. Ms Gundt gave similar evidence to that of Dr von Falck.